Feedback II – The GVAX Cancer Vaccine Trial at the Dana Farber

The GVAX cancer vaccine clinical trial, which has been opened in January 2006 is no more recruiting new patients. When it was open it recruited in addition to Alveolar Soft Part Sarcoma also Clear Cell Sarcoma, Renal Cell Carcinoma and Melanoma patients.
In June 2007 I shared with you an e-mail from a parent whose child, a clear cell sarcoma patient participated in the GVAX clinical trial. Here is a new update of that case. For the request of the family we keep that story confidential:

“My son participated in the GVAX trial in 2006. His story appeared on this web-site about a year and a half ago. He is a clear cell sarcoma patient. His primary tumor diagnosis, at the left upper thigh was found in 2002. Later in 2006, 2 adjacent lymph nodes and 3 lungs mets were identified. In addition, a questionable fourth lung met was also seen in his lung. The two lymph nodes were resected in 2006 and were used to prepare his cancer vaccine in the GVAX clinical trial. He had 13 injections of the cancer vaccine and no other treatment except for surgeries to remove the primary tumor and mets. Following the GVAX trial, one of his lung mets in the size of 4mm disappeared, one met in the size of 6 mm was resected and one 3 mm met has not being changed in size since then.
My son’s last scans were done in August 2008 and I’m pleased to report that the radiology report reads that there is no evidence of additional metastatic disease.
 
I know that “Argonaut” has shared Anthony’s success story of the GVAX clinical trial on the iCureASPS Forum: (Anthony – 32 months without growth) Like “Argonaut” also I am grateful that our both sons are experiencing a good outcome.
 
My speculation is that the cancer vaccine GVAX was in fact effective at least in our two cases and that intact immune system could be one of important factors to achieve a positive vaccine outcome. I know that this is “Argonaut’s” theory and since I have benefited by reading his son’s experience, I wanted to let him know that there is someone out there experiencing the same good news. Granted, a slightly different disease but the participation in the same GVAX trial puts us in the same group.
 
Let’s take a look at some of them. pfizer viagra This medicine for impotence needs to be taken prior practice of viagra in france without prescription? Sildenafil citrate, the component exists in the pill may origins with various allergic reaction signs in consumer. But cialis tablets australia have no receptors for sexual stimulation when a physician always recommends kamagra to the ED sufferer, he always recommend to the patient take medicine, only when he is facing insufficiency in blood. Physical activity is equally viagra in india important in this case. I hope we can explore the science behind what happened rather than just being grateful. Hopefully this information can and will be used to create better outcomes for all. ”

______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail:
landesmany@yahoo.com
 

Related ASPS News

On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.)...

Dear ASPS community, please read the recent update of this clinical trial from September 2020:...

The American Society of Clinical Oncology (ASCO) annual meeting took place this year in Chicago...